As of 2024-12-14, the Relative Valuation of Lineage Cell Therapeutics Inc (LCTX) is - USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.51 USD, the upside of Lineage Cell Therapeutics Inc based on Relative Valuation is -.
The range of the Relative Valuation is - USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | P/E |
| 2024-11-29 | -5.37 |
| 2024-11-27 | -5.34 |
| 2024-11-26 | -5.68 |
| 2024-11-25 | -5.39 |
| 2024-11-22 | -4.73 |
| 2024-11-21 | -5.63 |
| 2024-11-20 | -6.02 |
| 2024-11-19 | -8.48 |
| 2024-11-18 | -8.26 |
| 2024-11-15 | -8.12 |
| 2024-11-14 | -8.31 |
| 2024-11-13 | -8.57 |
| 2024-11-12 | -8.91 |
| 2024-11-11 | -8.86 |
| 2024-11-08 | -8.67 |
| 2024-11-07 | -8.50 |
| 2024-11-06 | -8.69 |
| 2024-11-05 | -7.93 |
| 2024-11-04 | -7.87 |
| 2024-11-01 | -7.66 |
| 2024-10-31 | -7.81 |
| 2024-10-30 | -8.00 |
| 2024-10-29 | -8.28 |
| 2024-10-28 | -8.26 |
| 2024-10-25 | -7.90 |
| 2024-10-24 | -8.04 |
| 2024-10-23 | -8.17 |
| 2024-10-22 | -8.32 |
| 2024-10-21 | -8.14 |
| 2024-10-18 | -8.52 |
| 2024-10-17 | -7.87 |
| 2024-10-16 | -8.21 |
| 2024-10-15 | -7.82 |
| 2024-10-14 | -8.07 |
| 2024-10-11 | -8.03 |
| 2024-10-10 | -7.94 |
| 2024-10-09 | -8.26 |
| 2024-10-08 | -8.16 |
| 2024-10-07 | -8.22 |
| 2024-10-04 | -8.54 |
| 2024-10-03 | -8.44 |
| 2024-10-02 | -8.66 |
| 2024-10-01 | -8.41 |
| 2024-09-30 | -8.50 |
| 2024-09-27 | -8.64 |
| 2024-09-26 | -8.09 |
| 2024-09-25 | -8.32 |
| 2024-09-24 | -8.39 |
| 2024-09-23 | -8.85 |
| 2024-09-20 | -8.83 |